Literature DB >> 34661871

Effect of delaying surgery by more than 10 weeks after neoadjuvant therapy in rectal cancer: a single institution experience.

Cristina Piva1, Luca Panier Suffat2, Edoardo T F Petrucci3, Giovanna Manuguerra4, Federico Vittone5, Domenico Cante1, Silvia Ferrario1, Marina Paolini1, Lorenzo Radici3, Giorgio Vellani4, Maria R La Porta1.   

Abstract

The optimal timing of surgery after neoadjuvant chemoradiotherapy (CRT) in locally advanced rectal cancer is still controversial. Aim of this study was to evaluate the effect of increasing time interval between the end of CRT and surgery on pathological outcomes. This is a retrospective analysis on 114 patients treated with long-course neoadjuvant RT with or without chemotherapy between January 2005 and September 2020. 43 patients underwent surgery within 10 weeks from the end of CRT (1st group), whereas 71 patients underwent total mesorectal excision with a time interval equal or greater than 10 weeks (2nd group). Primary endpoint was pCR (pathological complete response). Secondary endpoints were near pCR (ypT0-1 N0), tumor downstaging (ypT less than cT), nodal downstaging (ypN less than cN), and overall response comparing clinical with pathological TN stage. Overall, the pCR rate was 8.8%, whereas we observed no significantly difference in primary endpoint between the two groups. Considering near pCR, a trend toward significant difference in favor of 2nd group was seen (p = 0.072). Tumor and nodal downstaging rates were 39.5%, 41.9%, 59.2%, and 56.3% in the 1st and 2nd group, respectively, with a statistically significant difference for T category (p = 0.042). Overall response rates (TN stage) showed a trend toward significant difference in favor of patients of the ≥ 10 week group (p = 0.059). Our study suggests that a prolonged time interval between the end of CRT and surgery (≥ 10 weeks) increases pathological response rates.
© 2021. Italian Society of Surgery (SIC).

Entities:  

Keywords:  Neoadjuvant chemoradiotherapy; Rectal cancer; Surgery; Time interval

Mesh:

Year:  2021        PMID: 34661871     DOI: 10.1007/s13304-021-01189-y

Source DB:  PubMed          Journal:  Updates Surg        ISSN: 2038-131X


  20 in total

1.  Preoperative versus postoperative chemoradiotherapy for rectal cancer.

Authors:  Rolf Sauer; Heinz Becker; Werner Hohenberger; Claus Rödel; Christian Wittekind; Rainer Fietkau; Peter Martus; Jörg Tschmelitsch; Eva Hager; Clemens F Hess; Johann-H Karstens; Torsten Liersch; Heinz Schmidberger; Rudolf Raab
Journal:  N Engl J Med       Date:  2004-10-21       Impact factor: 91.245

2.  Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials.

Authors:  Vincenzo Valentini; Ruud G P M van Stiphout; Guido Lammering; Maria Antonietta Gambacorta; Maria Cristina Barba; Marek Bebenek; Franck Bonnetain; Jean-Francois Bosset; Krzysztof Bujko; Luca Cionini; Jean-Pierre Gerard; Claus Rödel; Aldo Sainato; Rolf Sauer; Bruce D Minsky; Laurence Collette; Philippe Lambin
Journal:  J Clin Oncol       Date:  2011-07-11       Impact factor: 44.544

3.  Complete pathologic response after combined modality treatment for rectal cancer and long-term survival: a meta-analysis.

Authors:  Luigi Zorcolo; Alan S Rosman; Angelo Restivo; Michele Pisano; Giuseppe R Nigri; Alessandro Fancellu; Marcovalerio Melis
Journal:  Ann Surg Oncol       Date:  2012-03-21       Impact factor: 5.344

Review 4.  Neoadjuvant therapy in rectal cancer.

Authors:  Fergal J Fleming; Lars Påhlman; John R T Monson
Journal:  Dis Colon Rectum       Date:  2011-07       Impact factor: 4.585

5.  Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial.

Authors:  Y Francois; C J Nemoz; J Baulieux; J Vignal; J P Grandjean; C Partensky; J C Souquet; P Adeleine; J P Gerard
Journal:  J Clin Oncol       Date:  1999-08       Impact factor: 44.544

6.  Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data.

Authors:  Monique Maas; Patty J Nelemans; Vincenzo Valentini; Prajnan Das; Claus Rödel; Li-Jen Kuo; Felipe A Calvo; Julio García-Aguilar; Rob Glynne-Jones; Karin Haustermans; Mohammed Mohiuddin; Salvatore Pucciarelli; William Small; Javier Suárez; George Theodoropoulos; Sebastiano Biondo; Regina G H Beets-Tan; Geerard L Beets
Journal:  Lancet Oncol       Date:  2010-08-06       Impact factor: 41.316

7.  An interval >7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer.

Authors:  Hagit Tulchinsky; Einat Shmueli; Arie Figer; Joseph M Klausner; Micha Rabau
Journal:  Ann Surg Oncol       Date:  2008-04-04       Impact factor: 5.344

8.  Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer.

Authors:  Matthew F Kalady; Luiz Felipe de Campos-Lobato; Luca Stocchi; Daniel P Geisler; David Dietz; Ian C Lavery; Victor W Fazio
Journal:  Ann Surg       Date:  2009-10       Impact factor: 12.969

Review 9.  Timing of surgery after long-course neoadjuvant chemoradiotherapy for rectal cancer: a systematic review of the literature.

Authors:  Jake D Foster; Emma L Jones; Stephen Falk; Edwin J Cooper; Nader K Francis
Journal:  Dis Colon Rectum       Date:  2013-07       Impact factor: 4.585

10.  Increasing the Interval Between Neoadjuvant Chemoradiotherapy and Surgery in Rectal Cancer: A Meta-analysis of Published Studies.

Authors:  Fausto Petrelli; Giovanni Sgroi; Enrico Sarti; Sandro Barni
Journal:  Ann Surg       Date:  2016-03       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.